A detailed history of New Edge Advisors, LLC transactions in Genmab A/S stock. As of the latest transaction made, New Edge Advisors, LLC holds 17,133 shares of GMAB stock, worth $352,768. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17,133
Previous 15,366 11.5%
Holding current value
$352,768
Previous $386,000 8.03%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.84 - $28.48 $42,125 - $50,324
1,767 Added 11.5%
17,133 $417,000
Q2 2024

Aug 15, 2024

BUY
$25.13 - $30.27 $359,132 - $432,588
14,291 Added 1329.4%
15,366 $386,000
Q1 2024

May 14, 2024

SELL
$26.43 - $32.77 $8,193 - $10,158
-310 Reduced 22.38%
1,075 $32,000
Q4 2023

Feb 13, 2024

BUY
$27.94 - $35.44 $19,865 - $25,197
711 Added 105.49%
1,385 $44,000
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $2,821 - $3,379
80 Added 13.47%
674 $23,000
Q2 2023

Aug 14, 2023

SELL
$37.4 - $42.94 $89,984 - $103,313
-2,406 Reduced 80.2%
594 $22,000
Q1 2023

May 12, 2023

BUY
$34.88 - $43.22 $3,836 - $4,754
110 Added 3.81%
3,000 $113,000
Q4 2022

Feb 14, 2023

BUY
$33.8 - $47.06 $97,681 - $136,003
2,890 New
2,890 $122,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.